A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03616912 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 6, 2018
Last Update Posted : June 18, 2021
|
Sponsor:
Eli Lilly and Company
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | May 19, 2022 |
| Estimated Study Completion Date : | June 19, 2022 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):